Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | POLB | P06746 | 4/20 | 0.56 |
| ▸ | RECQL | P46063 | 3/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.56 |
| ▸ | ATM | Q13315 | 1/20 | 0.56 |
| ▸ | BCL2 | P10415 | 1/20 | 0.52 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.52 |
| ▸ | ESR1 | P03372 | 5/20 | 0.50 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | APEX1 | P27695 | 2/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.50 |
| ▸ | ELANE | P08246 | 2/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.50 |
| ▸ | GMNN | O75496 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30669738 | 1.00 | MAPT (0.56) | MAPTPOLBRECQLKDM4EATM | |
| Flaviolin SCHEMBL703160 | 0.84 | BCL2 (0.52) | MAPTPOLBRECQLBCL2MCL1 | |
| SCHEMBL5820933 | 0.80 | BCL2 (0.52) | MAPTPOLBRECQLKDM4EBCL2 | |
| SCHEMBL2771631 | 0.78 | BCL2 (0.76) | MAPTPOLBRECQLBCL2MCL1 | |
| SCHEMBL5968219 | 0.76 | ESR1 (0.77) | MAPTPOLBRECQLKDM4EBCL2 | |
| SCHEMBL29390162 | 0.76 | ESR1 (0.77) | MAPTPOLBRECQLKDM4EBCL2 | |
| SCHEMBL10402209 | 0.73 | BCL2 (0.49) | MAPTPOLBRECQLBCL2MCL1 | |
| SCHEMBL5810073 | 0.72 | BCL2 (0.62) | MAPTPOLBRECQLKDM4EBCL2 | |
| SCHEMBL29611127 | 0.72 | BCL2 (0.62) | MAPTPOLBRECQLKDM4EBCL2 | |
| SCHEMBL8663341 | 0.72 | MAPT (1.00) | MAPTPOLBRECQLKDM4EATM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | claimed |
| WO-2022094079-A1 | METHODS OF TREATING CYSTIC FIBROSIS | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2022-05-05 | — | — | WO | claimed |
| US-20240043850-A1 | COMPOSITIONS AND METHODS FOR TYPE III POLYKETIDE PRODUCTION IN OLEAGINOUS YEAST SPECIES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2024-02-08 | — | — | US | disclosed |
| US-11820987-B2 | Compositions and methods for type III polyketide production in oleaginous yeast species | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2023-11-21 | — | — | US | disclosed |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | DARTMOUTH COLLEGE (US) | 2023-10-26 | — | — | US | disclosed |
| EP-3681504-B1 | METHODS OF DETECTION USING X-RAY FLUORESCENCE | ICAGEN INC (US) | 2023-08-23 | — | — | EP | disclosed |
| WO-2022094079-A1 | METHODS OF TREATING CYSTIC FIBROSIS | THE TRUSTEES OF DARTMOUTH COLLEGE (US) | 2022-05-05 | — | — | WO | disclosed |
| US-20210009939-A1 | COMPOSITIONS AND METHODS FOR MAXIMIZING MALONYL-COA IN E. COLI | BOARD OF SUPERVISORS OF LOUISIANA STATE UNIVERSITY AND AGRICULTURAL AND MECHANICAL COLLEGE | 2021-01-14 | — | — | US | disclosed |
| US-20190078098-A1 | COMPOSITIONS AND METHODS FOR TYPE III POLYKETIDE PRODUCTION IN OLEAGINOUS YEAST SPECIES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM | 2019-03-14 | — | — | US | disclosed |
| EP-2689020-B1 | MICROBIAL PRODUCTION OF CHEMICAL PRODUCTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | OPX BIOTECHNOLOGIES INC (US) | 2018-05-16 | — | — | EP | disclosed |
| WO-2017160801-A1 | COMPOSITIONS AND METHODS FOR TYPE III POLYKETIDE PRODUCTION IN OLEAGINOUS YEAST SPECIES | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2017-09-21 | — | — | WO | disclosed |
| US-20150056651-A1 | MICROORGANISM PRODUCTION OF HIGH-VALUE CHEMICAL PRODUCTS, AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | OPX BIOTECHNOLOGIES INC (US) | 2015-02-26 | — | — | US | disclosed |
| US-20140330032-A1 | MICROBIAL PRODUCTION OF CHEMICAL PRODUCTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | OPX BIOTECHNOLOGIES, INC. | 2014-11-06 | — | — | US | disclosed |
| EP-2689020-A1 | MICROBIAL PRODUCTION OF CHEMICAL PRODUCTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | OPX Biotechnologies Inc. (US) | 2014-01-29 | — | — | EP | disclosed |
| US-20130122541-A1 | MICROORGANISM PRODUCTION OF HIGH-VALUE CHEMICAL PRODUCTS, AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | THE REGENTS OF THE UNIVERSITY OF COLORADO | 2013-05-16 | — | — | US | disclosed |
| EP-2529023-A1 | MICROORGANISM PRODUCTION OF HIGH-VALVE CHEMICAL PRODUCTS, AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | OPX Biotechnologies Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| WO-2012129450-A1 | MICROBIAL PRODUCTION OF CHEMICAL PRODUCTS AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | OPX BIOTECHNOLOGIES, INC. (US) | 2012-09-27 | — | — | WO | disclosed |
| WO-2011094457-A1 | MICROORGANISM PRODUCTION OF HIGH-VALVE CHEMICAL PRODUCTS, AND RELATED COMPOSITIONS, METHODS AND SYSTEMS | OPX BIOTECHNOLOGIES, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230338340-A1 | Methods of Treating Cystic Fibrosis | CFTR, DAB2IP, CTTN | MAPT 4546/4885POLB 4458/4885RECQL 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.